Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with

F M Mattes1, E G Hainsworth, A F Hassan-Walker

  • 1Centre for Virology, Division of Infection and Immunity, Royal Free and University College Medical School, London NW32QG, UK.

The Journal of Infectious Diseases
|December 14, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early invasive fungal infections and colonization in patients with cirrhosis admitted to the intensive care unit.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2015
Same author

Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation.

Journal of viral hepatitis·2015
Same author

Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis.

Alimentary pharmacology & therapeutics·2015
Same author

Effects of donor/recipient human leukocyte antigen mismatch on human cytomegalovirus replication following liver transplantation.

Transplant infectious disease : an official journal of the Transplantation Society·2015
Same author

De novo use of generic tacrolimus in liver transplantation - a single center experience with one-yr follow-up.

Clinical transplantation·2014
Same author

Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort.

Alimentary pharmacology & therapeutics·2014

Valganciclovir (VGCV) offers a simplified approach to treating human cytomegalovirus (HCMV) infection post-transplant. This study found VGCV provides comparable HCMV load reduction kinetics to intravenous ganciclovir (GCV).

Area of Science:

  • Virology
  • Immunology
  • Transplantation Medicine

Background:

  • Human cytomegalovirus (HCMV) infection is a significant complication following solid-organ transplantation.
  • Preemptive therapy is crucial for managing HCMV infection in transplant recipients.
  • Valganciclovir (VGCV) offers an oral alternative to intravenous ganciclovir (GCV).

Purpose of the Study:

  • To compare the efficacy of preemptive oral valganciclovir (VGCV) versus intravenous ganciclovir (GCV) in controlling HCMV replication after solid-organ transplantation.
  • To evaluate the kinetics of HCMV load decrease in patients receiving VGCV compared to GCV.

Main Methods:

  • A comparative study involving solid-organ transplant recipients undergoing preemptive therapy for HCMV infection.
  • Patients were treated with either oral VGCV or intravenous GCV.

Related Experiment Videos

  • HCMV viral load kinetics were analyzed, with a focus on the time to achieve viral suppression (T1/2).

    • Main Results:

    • No statistically significant difference was observed in the kinetics of HCMV load decrease between patients treated with VGCV (T1/2=2.16 days) and those treated with GCV (T1/2=1.73 days; P=.63).
    • Preemptive therapy with VGCV demonstrated comparable control of HCMV replication to intravenous GCV.
    • The study included 22 recipients treated with VGCV and 23 treated with GCV.

    Conclusions:

    • Oral valganciclovir (VGCV) provides an effective and comparable alternative to intravenous ganciclovir (GCV) for preemptive treatment of HCMV infection in solid-organ transplant recipients.
    • VGCV simplifies treatment protocols while maintaining efficacy in controlling HCMV replication.
    • These findings support the use of VGCV in post-transplant HCMV management.